| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_62021bfb0c05ff81ee0105a012badbc1 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10332
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-761
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2016-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e1f2731f7bcca14a26db3458aef3c43
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cea24e89d4215c97f51e1b9c644833d9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5424653cfdca5f251c10efd3053bdae2 |
| publicationDate |
2018-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2018153946-A1 |
| titleOfInvention |
Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment |
| abstract |
The present invention relates to oncolytic adenoviruses with functional deletions of immunodominant T-cell epitopes of adenovirus proteins, as well as to methods of using the oncolytic adenoviruses for the treatment of diseases, such as cancer. The oncolytic adenoviruses may also contain one or more heterologous nucleic acid sequences each encoding a tumor antigen or epitope. The oncolytic adenoviruses may also contain other mutations and insertions of DNA sequences used to confer selectivity and antitumor potency. The invention has application in the field of cancer therapy. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018162921-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10626159-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11214789-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11085035-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10785574-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10704021-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10975368-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10724029-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11377651-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10888549-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11459540-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11474085-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11708572-B2 |
| priorityDate |
2015-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |